Semaglutide delivers superior weight loss results compared to Contrave, with clinical trials showing 15-17% average weight reduction versus 5-9% for the naltrexone/bupropion combination
Tirzepatide has shown promising results in clinical trials, offering a new therapeutic option for those struggling to achieve glycemic control with existing treatments
Your stack should connect to lab networks like LabCorp, Quest Diagnostics, BioReference, and Getlabs for at-home phlebotomy, so providers can order and track results directly within the clinical record
The absence of effects on IGF-1, glucose metabolism, and tissue growth reduces concerns about long-term hormonal consequences, but prudent medical oversight remains appropriate for any extended peptide use
For a systemic, synergistic effect with Methylene Blue, a research protocol would likely utilize an injectable form for broader distribution
Patients report significant reductions in cravings and food-related thoughts, unlocking time and mental energy to focus on more fulfilling life activities